These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 34179826)

  • 1. A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
    Zhou J; Gelot C; Pantelidou C; Li A; Yücel H; Davis RE; Färkkilä A; Kochupurakkal B; Syed A; Shapiro GI; Tainer JA; Blagg BSJ; Ceccaldi R; D'Andrea AD
    Nat Cancer; 2021 Jun; 2(6):598-610. PubMed ID: 34179826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair.
    Ceccaldi R; Liu JC; Amunugama R; Hajdu I; Primack B; Petalcorin MI; O'Connor KW; Konstantinopoulos PA; Elledge SJ; Boulton SJ; Yusufzai T; D'Andrea AD
    Nature; 2015 Feb; 518(7538):258-62. PubMed ID: 25642963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a small-molecule inhibitor that traps Polθ on DNA and synergizes with PARP inhibitors.
    Fried W; Tyagi M; Minakhin L; Chandramouly G; Tredinnick T; Ramanjulu M; Auerbacher W; Calbert M; Rusanov T; Hoang T; Borisonnik N; Betsch R; Krais JJ; Wang Y; Vekariya UM; Gordon J; Morton G; Kent T; Skorski T; Johnson N; Childers W; Chen XS; Pomerantz RT
    Nat Commun; 2024 Apr; 15(1):2862. PubMed ID: 38580648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and Proof of Concept of Potent Dual Polθ/PARP Inhibitors for Efficient Treatment of Homologous Recombination-Deficient Tumors.
    Ma L; Chen W; Yang M; Ha S; Xiong S; Zhu J; Xiang H; Luo G
    J Med Chem; 2024 Mar; 67(5):3606-3625. PubMed ID: 38375763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Talazoparib enhances resection at DSBs and renders HR-proficient cancer cells susceptible to Polθ inhibition.
    Lin X; Soni A; Hessenow R; Sun Y; Mladenov E; Guberina M; Stuschke M; Iliakis G
    Radiother Oncol; 2024 Nov; 200():110475. PubMed ID: 39147034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
    Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
    Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity.
    Syed A; Filandr F; Patterson-Fortin J; Bacolla A; Ravindranathan R; Zhou J; McDonald DT; Albuhluli ME; Verway-Cohen A; Newman JA; Tsai MS; Jones DE; Schriemer DC; D'Andrea AD; Tainer JA
    Nucleic Acids Res; 2023 Oct; 51(18):9920-9937. PubMed ID: 37665033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase theta is a synthetic lethal target for killing Epstein-Barr virus lymphomas.
    Willman GH; Xu H; Zeigler TM; McIntosh MT; Bhaduri-McIntosh S
    J Virol; 2024 Jul; 98(7):e0057224. PubMed ID: 38860782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
    Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
    Sun C; Yin J; Fang Y; Chen J; Jeong KJ; Chen X; Vellano CP; Ju Z; Zhao W; Zhang D; Lu Y; Meric-Bernstam F; Yap TA; Hattersley M; O'Connor MJ; Chen H; Fawell S; Lin SY; Peng G; Mills GB
    Cancer Cell; 2018 Mar; 33(3):401-416.e8. PubMed ID: 29533782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous Targeting of DNA Polymerase Theta and PARP1 or RAD52 Triggers Dual Synthetic Lethality in Homologous Recombination-Deficient Leukemia Cells.
    Sullivan-Reed K; Toma MM; Drzewiecka M; Nieborowska-Skorska M; Nejati R; Karami A; Wasik MA; Sliwinski T; Skorski T
    Mol Cancer Res; 2023 Oct; 21(10):1017-1022. PubMed ID: 37358557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
    Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification.
    Pellegrino B; Herencia-Ropero A; Llop-Guevara A; Pedretti F; Moles-Fernández A; Viaplana C; Villacampa G; Guzmán M; Rodríguez O; Grueso J; Jiménez J; Arenas EJ; Degasperi A; Dias JML; Forment JV; O'Connor MJ; Déas O; Cairo S; Zhou Y; Musolino A; Caldas C; Nik-Zainal S; Clarke RB; Nuciforo P; Díez O; Serres-Créixams X; Peg V; Espinosa-Bravo M; Macarulla T; Oaknin A; Mateo J; Arribas J; Dienstmann R; Bellet M; Oliveira M; Saura C; Gutiérrez-Enríquez S; Balmaña J; Serra V
    Cancer Res; 2022 Apr; 82(8):1646-1657. PubMed ID: 35425960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAD51-Mediated DNA Homologous Recombination Is Independent of
    Sinha A; Saleh A; Endersby R; Yuan SH; Chokshi CR; Brown KR; Kuzio B; Kauppinen T; Singh SK; Baker SJ; McKinnon PJ; Katyal S
    Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33138032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional inhibition of RECQL5 helicase elicits non-homologous end joining response and sensitivity of breast cancers to PARP inhibitor.
    Philip KT; Dutta K; Chakraborty S; Patro BS
    Int J Biochem Cell Biol; 2023 Aug; 161():106443. PubMed ID: 37392863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tackling PARP inhibitor resistance.
    Fugger K; Hewitt G; West SC; Boulton SJ
    Trends Cancer; 2021 Dec; 7(12):1102-1118. PubMed ID: 34563478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
    Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.